The role of fibric acid derivatives in the secondary prevention of coronary heart disease

Current Cardiology Reports

Volumn 2, Issue 5, 2000, Pages 452-458

  Krakoff, Jonathan ^a   Vela, B Sylvia ^b   Brinton, Eliot A ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; REVIEW;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; GEMFIBROZIL; HUMANS; TRIGLYCERIDES;

EID: 0034264379     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0060-z     Document Type: Article

References (50)

1. Barr DP, Russ EM, Eder HA: Protein-lipids relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med 1951, 11:480-493.
2. Gordon T, Castelli WP, Hjortland MC, et al.: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
3. Castelli WP, Garrison RJ, Wilson PW, et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986, 256:2835-2838.
4. Castelli WP, et al.: Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992, 2:23-28.
5. Miller NE, et al.: The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977, 1:965-968.
6. Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979, 90:85-91.
7. Stampfer MJ, Sacks FM, Salvini S, et al.: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction [see comments]. N Engl J Med 1991, 325:373-381.
8. Criqui MH, Heiss G, Cohn R, et al.: Plasma triglyceride level and mortality from coronary heart disease [see comments]. N Engl J Med 1993, 328:1220-1225.
9. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of populationbased prospective studies. J Cardiovasc Risk 1996, 3:213-219.
10. Jeppesen J, Hein HO, Suadicani P, et al.: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study [see comments] [published erratum appears in Circulation 1998, 97:1995] [see comments]. Circulation 1998, 97:1029-1036.
11. Gotto AM Jr: Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998, 82:22Q-25Q.
12. Havel RJ: Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994, 5:102-109.
13. Tikkanen MJ, Laakso M, Ilmonen M, et al.: Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998, 21:477-481.
14. Caslake MJ, Packard CJ, Gaw A, et al.: Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993, 13:702-711.
15. de Graaf J, Hendriks JC, Demacker PN, et al.: Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb 1993, 13:712-719.
16. Landray MJ, Sagar G, Muskin J, et al.: Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. QJM 1998, 91:345-351.
17. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women [see comments]. JAMA 1996, 276:875-881.
18. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study [see comments]. Circulation 1997, 95:69-75.
19. Hurt-Camejo E, Camejo G, Rosengren B, et al.: Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990, 31:1387-1398.
20. Anber V, Millar JS, McConnell M, et al.: Interaction of very-lowdensity, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol 1997, 17:2507-2514.
21. de Graaf J, Hak-Lemmers HL, Hectors MP, et al.: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991, 11:298-306.
22. Dejager S, Bruckert E, Chapman MJ: Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993, 34:295-308.
23. Tribble DL, Holl LG, Wood PD, et al.: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992, 93:189-199.
24. Auboeuf D, Rieusset J, Fajas L, et al.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319-1327.
25. Peters JM, Hennuyern N, Staels B, et al.: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997, 272:27307-27312.
26. Malmendier CL, Lontie JF, Delcroix C, et al.: Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989, 77:139-149.
27. Vu-Dac N, Schoonjans K, Kosykh V, et al.: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995, 96:741-750.
28. Kowal RC, Herz J, Weisgraber KH, et al.: Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990, 265:10771-10779.
29. Brewer HB Jr: Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999, 83:3F-12F.
30. Lussier-Cacan S, Bard JM, Boulet L, et al.: Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis 1989, 78:167-182.
31. Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
32. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978, 40:1069-1118.
33. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984, 2:600-604.
34. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary- prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
35. Manninen V, Elo MO, Frick MH, et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260:641-651.
36. Tenkanen L, Manttari M, Manninen V: Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995, 92:1779-1785.
37. Elkeles RS, Diamond JR, PoulterC, et al.: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998, 21:641-648.
38. Frick MH, Helonen OP, Huttunen JK, et al.: Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med 1993, 25:41-45.
39. Ericsson CG, Hamsten A, Nilsson J, et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853.
40. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) [published erratum appears in Lancet 1994, 344:762] [see comments]. Lancet 1994, 344:633-638.
41. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [see comments]. N Engl J Med 1998, 339:1349-1357.
42. Ericsson CG, Nilsson J, Grip L, et al.: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997, 80:1125-1129.
43. Hodis HN, Mack WJ, Azen SP, et al.: Triglyceride- and cholesterol- rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42-49.
44. Blankenhorn DH, Azen SP, Kramsch DM, et al.: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group [see comments]. Ann Intern Med 1993, 119:969-976.
45. Frick MH, Syvanne M, Nierninen MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group [see comments]. Circulation 1997, 96:2137-2143.
46. Goldbourt U, Behar S, Reicher-Reiss H, et al.: Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993, 71:909-915.
47. Verheugt FW: Hotline sessions at the 20th European Congress of Cardiology. Eur Heart J 1999, 20:7-10.
48. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Stu Group. N Engl J Med 1999, 341:410-418
49. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators [see comments]. N Engl J Med 1996, 335:1001-1009.
50. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [see comments]. Lancet 1994, 344:1383-1389.